<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00289471</url>
  </required_header>
  <id_info>
    <org_study_id>IIR 05-112</org_study_id>
    <nct_id>NCT00289471</nct_id>
  </id_info>
  <brief_title>Identifying Patients With Dementia in Primary Care</brief_title>
  <acronym>GEMS</acronym>
  <official_title>Dementia in Primary Care: Setting the Stage for Quality Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Veterans who completed GEMS-Phase 1 will be asked to participate in GEMS-Phase 2 to determine&#xD;
      the accuracy of methods used to assess mild memory problems. This will better help us&#xD;
      evaluate the screening test completed in GEMS-Phase 1. The goals are:&#xD;
&#xD;
        1. Compare the assessment of memory made at the initial visit to assessments of memory made&#xD;
           at the second evaluation.&#xD;
&#xD;
        2. Determine of veterans with mild memory problems have improvement or worsening of these&#xD;
           memory problems over time. Our long-term goal remains to optimize the quality of care&#xD;
           for veterans with cognitive impairment. We will also determine if patient&#xD;
           characteristics can be used to target case-finding, describe the current process of care&#xD;
           and evaluate the association between cognitive impairment and overall- and&#xD;
           dementia-related health care utilization and costs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dementia has high public health significance due to its prevalence, adverse impact on&#xD;
      patients and caregivers, high economic cost to society and the rapidly expanding numbers of&#xD;
      individuals age 65 and older. As the largest provider of geriatric care in the U.S., dementia&#xD;
      is particularly relevant to the Veterans Health Administration (VHA). However, only a small&#xD;
      proportion of patients with dementia are diagnosed early when treatments are most effective&#xD;
      and the opportunity for careful life planning remains, in part because of the absence of&#xD;
      feasible, well-validated case-finding instruments. Our long-term objective is to improve the&#xD;
      care and outcomes of veterans with clinically significant cognitive impairment. The first&#xD;
      steps towards realizing this objective are to determine the acceptability of cognitive&#xD;
      screening to patients and to identify feasible, valid case-finding tools for primary care. We&#xD;
      will also determine if patient characteristics can be used to target case-finding, describe&#xD;
      the current process of care and evaluate the association between cognitive impairment and&#xD;
      overall- and dementia-related health care utilization and costs. Our research team, located&#xD;
      in the Center for Health Services Research in Primary Care, brings together researchers&#xD;
      uniquely suited to achieving this objective. Specific Aims1.Primary Aim: To determine if&#xD;
      cognitive screening is acceptable to patients, and whether brief cognitive screeners perform&#xD;
      as well as the longer Modified Mini-Mental Status Exam (3MS) for dementia and cognitive&#xD;
      impairment-not dementia (CIND).Primary Hypothesis 1: Higher perceived risk of dementia,&#xD;
      higher perceived benefits and fewer perceived harms from screening will be positively&#xD;
      associated with screening acceptance. Primary Hypotheses 2: Compared to the 3MS, the&#xD;
      Mini-Cog, Memory Impairment Screen and 2-item functional screen will have similar performance&#xD;
      characteristics. 2.Secondary Aim 1: To determine if sociodemographic and clinical&#xD;
      characteristics available in the electronic medical record can be used to target individuals&#xD;
      for cognitive screening and improve screening accuracy. Hypothesis: The combination of&#xD;
      sociodemographic characteristics/clinical information and screening results will more&#xD;
      accurately discriminate between demented and non-demented patients than screening results&#xD;
      alone.3.Secondary Aim 2: To describe current care for an inception cohort with dementia or&#xD;
      cognitive impairment-not dementia. Hypothesis: Compared to patients with dementia, patients&#xD;
      with cognitive impairment-not dementia will undergo less diagnostic testing, be less likely&#xD;
      to complete an advanced directive and be less likely to receive dementia specific&#xD;
      medications. 4.Exploratory Aim: To evaluate the association between cognitive impairment and&#xD;
      overall- and dementia-related health care utilization and costs. Exploratory Hypothesis:&#xD;
      Controlling for sociodemographic characteristics and medical comorbidity, overall healthcare&#xD;
      utilization and costs will increase as cognitive impairment increases. In phase 1, a random&#xD;
      sample of primary care patients age 65 years will be recruited from 3 primary care clinics to&#xD;
      complete the Modified Dementia Screening Acceptance and Perceived Harms Questionnaire. In&#xD;
      phase 2, patients will complete three brief instruments and the standard 15-item 3MS that&#xD;
      will be compared to a criterion standard interview for dementia. We project 140-200 patients&#xD;
      will have dementia, 200-300 CIND, and approximately 600 will be cognitively normal.&#xD;
      Instruments will be compared using sensitivity/specificity, likelihood ratios and receiver&#xD;
      operating characteristic curves. The emotional impact of screening will be assessed following&#xD;
      screening. Clinical and sociodemographic characteristics available in the Computerized&#xD;
      Patient Record System, together with cognitive screening results, will be analyzed with&#xD;
      logistic regression models to identify risk factors that may be used to target individuals&#xD;
      for cognitive screening and/or improve screening accuracy. Care patterns for patients with&#xD;
      dementia and CIND will be described based on detailed chart abstractions. For the exploratory&#xD;
      analysis on cognitive impairment and utilization, two-part utilization models will be&#xD;
      estimated for each utilization type, outpatient clinic visits, inpatient visits, pharmacy&#xD;
      utilization, and other utilization types; utilization data will be obtained from&#xD;
      administrative data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance Characteristics</measure>
    <time_frame>Cross-sectional [at baseline; no longitudinal component]</time_frame>
    <description>Sensitivity and Specificity for Modified Mini-Mental Status Examination (MMSE), a measure scored 0-100 to assess cognitive impairment</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">630</enrollment>
  <condition>Dementia</condition>
  <condition>Memory Disorders</condition>
  <arm_group>
    <arm_group_label>Cognitive Screening</arm_group_label>
    <description>Cognitive screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention delivered.</intervention_name>
    <description>No intervention delivered.</description>
    <arm_group_label>Cognitive Screening</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Veterans' who have previously completed GEMS-Phase 1 testing, continues to be a VA clinic&#xD;
        patient and identifies a key family member or friend who will answer questions about the&#xD;
        veteran's memory and daily activities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previous participant who completed GEMS-Phase 1&#xD;
&#xD;
          -  Continues to be a VA clinic patient&#xD;
&#xD;
          -  Identifies a key informant with phone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe hearing or visual impairment&#xD;
&#xD;
          -  Acute medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Williams, MD MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VA Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA Medical Center HSR&amp;D COE</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Plassman BL, Williams JW Jr, Burke JR, Holsinger T, Benjamin S. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med. 2010 Aug 3;153(3):182-93. doi: 10.7326/0003-4819-153-3-201008030-00258. Epub 2010 Jun 14. Review.</citation>
    <PMID>20547887</PMID>
  </results_reference>
  <results_reference>
    <citation>Holsinger T, Plassman BL, Stechuchak KM, Burke JR, Coffman CJ, Williams JW Jr. Screening for cognitive impairment: comparing the performance of four instruments in primary care. J Am Geriatr Soc. 2012 Jun;60(6):1027-36. doi: 10.1111/j.1532-5415.2012.03967.x. Epub 2012 May 30.</citation>
    <PMID>22646750</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 8, 2006</study_first_submitted>
  <study_first_submitted_qc>February 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2006</study_first_posted>
  <results_first_submitted>August 11, 2014</results_first_submitted>
  <results_first_submitted_qc>August 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sensitivity and specificity</keyword>
  <keyword>Physician's practice patterns</keyword>
  <keyword>Health Care costs</keyword>
  <keyword>Quality of Health Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Screening</title>
          <description>Cognitive screening&#xD;
No intervention delivered.: No intervention delivered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="630"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="630"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Screening</title>
          <description>Cognitive screening&#xD;
No intervention delivered.: No intervention delivered.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="630"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Performance Characteristics</title>
        <description>Sensitivity and Specificity for Modified Mini-Mental Status Examination (MMSE), a measure scored 0-100 to assess cognitive impairment</description>
        <time_frame>Cross-sectional [at baseline; no longitudinal component]</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Screening</title>
            <description>Cognitive screening&#xD;
No intervention delivered.: No intervention delivered.</description>
          </group>
        </group_list>
        <measure>
          <title>Performance Characteristics</title>
          <description>Sensitivity and Specificity for Modified Mini-Mental Status Examination (MMSE), a measure scored 0-100 to assess cognitive impairment</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="64" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="72" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Cross-sectional [at baseline; no longitudinal component]</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Screening</title>
          <description>Cognitive screening&#xD;
No intervention delivered.: No intervention delivered.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="630"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John W. Williams</name_or_title>
      <organization>Durham VAMC</organization>
      <phone>919-286-6963</phone>
      <email>jw.williams@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

